Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7
Polaris entities and affiliated individuals have updated their beneficial ownership in Alector, Inc. (ALEC) through an Amendment No. 7 to Schedule 13G/A. As of April 30, 2026, Polaris-related funds and their managing members collectively report shared voting and dispositive power over 4,853,817 shares, representing a 4.4% stake based on Alector's 110,362,581 outstanding shares as of February 20, 2026. This amendment clarifies specific holdings across Polaris funds and details the shared control among key individuals.
Alector Establishes $125 Million At-the-Market Offering
Alector, Inc. has entered into a sales agreement with TD Securities (USA) LLC to establish a $125 million at-the-market offering for common stock. This provides Alector with financial flexibility for general corporate purposes, including R&D and potential acquisitions. Despite the financing option, a recent analyst rating on ALEC stock is a Sell with a $2.00 price target, and TipRanks' AI Analyst shows a Neutral rating due to weak financial performance.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting $206.5 million in cash, cash equivalents, and investments, which are expected to fund operations through 2027. The biotechnology company provided updates on its Alector Brain Carrier (ABC) platform, which is advancing multiple therapeutic modalities for neurodegenerative diseases like Alzheimer's and Parkinson's. The company also noted a decrease in revenue and operating expenses compared to Q1 2025, resulting in a reduced net loss for the quarter.
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev
Alector Inc. (ALEC) reported a Q1 revenue of $1.05 million, significantly missing the anticipated $11.03 million, raising concerns among investors despite CEO Arnon Rosenthal's emphasis on strategic progress in its blood-brain barrier platform. The company's GF Score™ of 36/100 highlights weaknesses in financial strength and profitability, further compounded by $0.3 million in insider selling and a high price-to-sales ratio, suggesting potential overvaluation and challenges in translating research into revenue.
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline
Alector reported a narrower net loss in Q1 2026, reaching $22.9 million compared to $40.5 million a year prior, primarily due to significant reductions in operating expenses following 2025 workforce reductions and program wind-downs. Despite a decline in collaboration revenue from its GSK partnership, the company's cash reserves of $206.5 million are expected to fund operations through at least 2027. Alector is now repositioning its pipeline to focus on its ABC blood-brain barrier platform and preclinical programs, after GSK discontinued the Phase 2 PROGRESS-AD trial for nivisnebart in April 2026 due to a futility analysis.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting $206.5 million in cash, cash equivalents, and investments, projected to fund operations through at least 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with programs like AL037/AL137, AL050, and AL164 targeting Alzheimer’s and Parkinson’s diseases, while also announcing the discontinuation of its PROGRESS-AD Phase 2 trial for nivisnebart due to a futility analysis. Financials show decreased revenue and R&D expenses compared to Q1 2025, resulting in a net loss of $22.9 million for the quarter.
Alector Establishes $125 Million At-the-Market Offering
Alector has announced a $125 million at-the-market stock offering program with TD Securities (USA) LLC, allowing the company to sell common stock to fund general corporate purposes, including R&D, manufacturing, and potential strategic transactions. This arrangement provides financial flexibility without immediate shareholder dilution. Despite a recent "Sell" rating and a $2.00 price target from analysts, TipRanks’ AI Analyst, Spark, rates ALEC as Neutral, noting weak financial performance but strong technicals.
Alector Establishes $125 Million At-the-Market Offering
Alector, a biotechnology company, has entered into a sales agreement with TD Securities (USA) LLC to sell up to $125 million of common stock through at-the-market or negotiated offerings. These proceeds will fund research and development, manufacturing, working capital, and potential acquisitions. An analyst rating on ALEC stock is a Sell with a $2.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial performance despite technical strengths.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) reported a Q1 loss of $0.21 per share, which was better than the Zacks Consensus Estimate of a $0.35 loss, representing an earnings surprise of +40.00%. However, the company missed revenue estimates, posting $1.05 million against an expected $3.01 million. Due to an unfavorable estimate revisions trend, Alector currently holds a Zacks Rank #4 (Sell), suggesting underperformance in the near future.
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen
Alector (NASDAQ: ALEC) has filed a $125 million "at-the-market" (ATM) common stock offering with TD Cowen. The proceeds are intended for general corporate purposes, including research, development, manufacturing, working capital, capital expenditures, and potential strategic transactions. This offering could dilute existing shareholders, with an assumed dilution of $1.74 per share for new investors based on a reference price of $2.57.
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility
Alector, Inc. (NASDAQ: ALEC) has established a new At-The-Market (ATM) sales agreement with TD Securities (USA) LLC, allowing it to offer and sell up to $125 million of common stock. The company plans to use the net proceeds for general corporate purposes, including research, development, and potential acquisitions. Sales will occur on The Nasdaq Global Select Market, with TD Cowen receiving up to 3.0% of the gross sales price as compensation.
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus
Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its first-quarter 2026 financial results, highlighting a cash position of $206.5 million, sufficient to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with programs like AL037/AL137 for Alzheimer's and AL050 for Parkinson's disease currently in preclinical development. Alector also announced the discontinuation of the PROGRESS-AD Phase 2 clinical trial for nivisnebart due to futility.
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC)
This article summarizes recent analyst ratings for two healthcare companies: Establishment Labs Holdings (ESTA) and Alector (ALEC). TD Cowen reiterated a Buy rating for ESTA with a $95 price target, while Mizuho Securities maintained a Hold rating for ALEC with a $1.50 price target. The article also provides a consensus analyst rating and average price target for both companies.
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com
Morgan Stanley increased its price target for Alector Inc. (ALEC) to $2.00 from $0.90, maintaining an Underweight rating despite a recent trial failure. The firm views the AL101 trial setback as a "clearing event" that allows Alector to reallocate research and development funds to its promising ABC platform, which analysts believe can overcome previous delivery challenges. This follows a similar upgrade from BTIG, signaling renewed confidence in Alector's strategic shift toward blood-brain barrier therapeutics.
Peninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programs
Alector, a Peninsula biotech company, has ceased another Alzheimer's drug clinical trial, marking its third such discontinuation in 18 months. This decision reflects a strategic shift towards earlier-stage programs following significant workforce reductions and subleasing of office space. The company's workforce has decreased by over 140 employees since early 2024.
Short Interest in Alector, Inc. (NASDAQ:ALEC) Drops By 18.0%
Short interest in Alector, Inc. (NASDAQ:ALEC) decreased by 18.0% in April, totaling 5,151,723 shares as of April 15th, representing 5.2% of the company's stock. The days-to-cover ratio is approximately 6.3 days. Analyst sentiment for Alector is mixed, with an average "Hold" rating and an average price target of $4.17 from several firms.
[EFFECT] Alector, Inc. SEC Filing
This article announces an EFFECT SEC Filing by Alector, Inc. (ALEC) with a neutral impact and sentiment. The filing, effective April 30, 2026, is a Form S-3 and provides details from the SEC Edgar database. The article also includes Alector's stock overview, recent news, and other SEC filings.
Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease.
Alector Inc. has decided to discontinue its Phase II PROGRESS-AD clinical trial for Nivisnebart (AL101/GSK4527226), a drug candidate for early-stage Alzheimer's disease. This decision was made following a pre-planned interim analysis which indicated that the trial did not meet its expected efficacy endpoints. The company will cease further development of this particular candidate for AD.
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Alector, Inc. is discontinuing its Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) for early Alzheimer’s disease. An independent data monitoring committee found the trial unlikely to meet its primary endpoint of slowing disease progression. Alector will now focus on advancing its pipeline of novel ABC-enabled candidates, including other Alzheimer’s and Parkinson’s disease therapies.
Alzheimer’s drug study stops early after review finds low odds of success
Alector (NASDAQ: ALEC) is discontinuing its Phase 2 PROGRESS-AD trial for nivisnebart in early Alzheimer's disease after an independent data monitoring committee found it unlikely to meet its primary endpoint. Despite this setback, Alector confirmed it will continue to advance its pipeline of ABC-enabled programs, including AL037/AL137 and AL050, targeting IND submissions in 2027.
Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease.
Alector Inc. has announced the discontinuation of its Phase II PROGRESS-AD clinical trial for Nivisnebart (AL101/GSK4527226), a drug candidate for early-stage Alzheimer's disease. This decision follows a prescheduled interim analysis which revealed the trial did not meet its targeted efficacy endpoints. The company will cease development of this particular candidate.
BlackRock (ALEC) discloses 5.2% ownership of Alector common stock
BlackRock, Inc. has filed a Schedule 13G disclosing a 5.2% beneficial ownership stake in Alector, Inc. (ALEC) as of March 31, 2026. This filing indicates BlackRock beneficially owns 5,784,214 shares, with sole voting power over 5,697,278 shares and sole dispositive power over all 5,784,214 shares. The disclosure, signed by Spencer Fleming, Managing Director, confirms that these shares were acquired for passive investment purposes, not to influence control of the issuer.
Alector Inc: Principal accounting officer Wong-Sarad sells $4823 in stock By Investing.com
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ: ALEC), sold 1,820 shares of common stock for $4,823 on April 16, 2026, under a Rule 10b5-1 trading plan. The sale occurred while the stock traded below InvestingPro’s Fair Value estimate, despite a significant 177% gain over the past year. This news follows an upgrade of Alector Inc. from Neutral to Buy by BTIG, with a $6.00 price target, due to the company's new strategy focusing on therapeutics with blood-brain barrier shuttle domains.
Alector (ALEC) accounting officer sells 1,820 shares in 10b5-1 trade
Alector, Inc.'s principal accounting officer, Grace Wong-Sarad, reported an open-market sale of 1,820 shares of common stock at $2.65 per share. This transaction was carried out under a pre-arranged Rule 10b5-1 Trading Plan. Following the sale, Grace Wong-Sarad directly holds 104,645 shares of Alector common stock.
Alector Inc: Principal accounting officer Wong-Sarad sells $4823 in stock
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 1,820 shares of common stock for $4,823 at a price of $2.65 per share on April 16, 2026, under a Rule 10b5-1 trading plan. The sale occurred while the stock traded below InvestingPro’s Fair Value estimate, despite a 177% gain over the past year. Concurrently, Alector Inc. received an upgrade from BTIG to a Buy rating with a $6.00 price target due to its strategic shift towards developing therapeutics with blood-brain barrier shuttle domains.
Alector Inc: Principal accounting officer Wong-Sarad sells $4823 in stock
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 1,820 shares of common stock for a total of $4,823. This transaction, executed under a Rule 10b5-1 trading plan, leaves Wong-Sarad with 104,645 shares directly owned. The sale comes as the stock trades below its InvestingPro’s Fair Value estimate, despite a significant 177% gain over the past year.
Alector Inc: Principal accounting officer Wong-Sarad sells $4823 in stock
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 1,820 shares of common stock for a total of $4823 on April 16, 2026, under a Rule 10b5-1 trading plan. The sale occurred while the stock traded at $2.57, following a 177% gain over the past year. This transaction follows a recent upgrade of Alector Inc. to a Buy rating by BTIG, with a $6.00 price target, due to the company's strategic shift toward developing therapeutics with blood-brain barrier shuttle domains.
ALEC (NASDAQ: ALEC) affiliate reports multiple common-stock sales in Mar 2026
Alector, Inc. (NASDAQ: ALEC) filed a Form 144, reporting proposed and recent common stock sales by an affiliate. The filing details restricted share issuances in March and June 2025, and multiple dispositions by Grace Wong-Sarad in February and March 2026, including 8,071 shares on March 2, 2026, and 3,367 shares on March 3, 2026. This activity is a routine regulatory notice for selling restricted or control securities.
Alector gains as Cantor Fitzgerald upgrades on brain carrier platform
The article indicates that Alector's stock is performing well due to an upgrade from Cantor Fitzgerald. The upgrade is attributed to Alector's brain carrier platform. No further details are provided in the content.
Cantor Fitzgerald Upgrades Alector (NASDAQ:ALEC) to "Overweight"
Cantor Fitzgerald has upgraded Alector (NASDAQ:ALEC) from "neutral" to "overweight," following a similar upgrade from BTIG Research. Despite the recent upgrades, the overall analyst sentiment for Alector is mixed with an average "Hold" rating and a target price of $4.17, while the company remains unprofitable. Institutional ownership is significant at 85.83%, with several large investors increasing their stakes in the last quarter.
ALEC Upgraded by Cantor Fitzgerald -- Rating Raised to Overweigh
Cantor Fitzgerald has upgraded Alector (ALEC) to an Overweight rating from Neutral, signaling a more positive outlook for the biotech company. Despite the analyst upgrade, GuruFocus indicates ALEC is significantly overvalued at $2.41 compared to its GF Value™ of $0.85, and its GF Score™ of 35/100 highlights weaknesses in financial metrics. Insider selling activity also suggests a lack of confidence among company insiders.
Alector stock upgraded at Cantor Fitzgerald (ALEC:NASDAQ)
Alector (ALEC) shares rose after Cantor Fitzgerald upgraded the biotech company to Overweight from Neutral. The upgrade is attributed to the potential of Alector's blood-brain barrier (BBB) technology platform, Alector Brain Carrier (ABC). This follows a trial setback for GSK in October.
Alector (ALEC) Price Target Decreased by 42.61% to 2.24
The article reports that Alector's (ALEC) price target has been significantly decreased by 42.61%, bringing it down to $2.24. This change indicates a notable revision in analyst expectations for the company's stock performance.
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Rating of "Hold" from Analysts
Alector, Inc. (NASDAQ:ALEC) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $4.17. The company recently reported Q4 EPS of ($0.34) and revenue of $6.24 million, exceeding estimates but remaining unprofitable. Institutional investors hold a significant 85.83% stake in the stock, with several firms increasing their positions in the last quarter.
Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)
Analysts are showing bullish sentiment towards two healthcare stocks, Amgen (AMGN) and Alector (ALEC). William Blair analyst Matt Phipps maintained a Buy rating on Amgen with an average price target indicating a 6.9% upside. BTIG analyst Thomas Shrader also maintained a Buy rating on Alector, setting an ambitious price target of $6.00, significantly higher than its current trading price.
Alector (Nasdaq:ALEC) - Stock Analysis
Alector, Inc. (ALEC) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. The company is currently unprofitable and its shares have experienced significant volatility. Despite recent analyst upgrades and some positive news regarding its pipeline, insider selling and a previous clinical trial failure of Latozinemab suggest ongoing challenges, with market analysts holding a mixed outlook on its valuation.
Working capital per share of Alector, Inc. – GETTEX:0Z2
This page provides financial data, specifically working capital per share, for Alector, Inc. (0Z2) on the Gettex exchange. It appears to be a financial data portal displaying key metrics for interested investors. The data listed for "Period Value Change Change %" is currently empty.
Alector (ALEC) Surges 19.8% in Intraday Trading: Is This a Breakout or a Fleeting Spike?
Alector (ALEC) shares surged 19.8% in intraday trading on April 1, 2026, reaching $2.575, driven by short-term technical momentum and speculative options positioning. High volume in April 17 call options at the $2.5 strike suggests traders are anticipating a continued rally. While technical indicators show bullish signs, historical backtesting of similar surges yielded mixed long-term results, leading investors to question if this is a true breakout or a temporary spike.
12 Health Care Stocks Moving In Wednesday's Intraday Session
This article identifies several healthcare stocks that experienced significant intraday movement on Wednesday, listing both gainers and losers. Cyclerion Therapeutics and Axe Compute saw substantial increases, while ORIC Pharmaceuticals and Bristol-Myers Squibb Company Celegne Contingent Value Rights were among those that declined. The movements are attributed to various factors including recent earnings reports.
Alector (ALEC)'s technical outlook is bright after key golden cross
This article analyzes Alector (ALEC) stock's recent technical performance, highlighting a "golden cross" event where its 50-day moving average surpassed its 200-day moving average. This technical indicator suggests a potentially strong short-to-medium-term upward trend for the stock, making it an attractive prospect for investors.
Alector (ALEC) price target increased by 37.14% to 2.94
This article reports a significant increase in the price target for Alector (ALEC) stock. The target has been raised by 37.14% to $2.94. This adjustment could indicate a more optimistic outlook on the company's future performance by analysts.
Alector (ALEC) price target increased by 37.14% to 2.94
Alector (ALEC) has received a price target increase of 37.14%, raising it to $2.94. This suggests a positive reevaluation of the company's stock outlook by analysts.
HC Wainwright & Co. Maintains Alector (ALEC) Buy Recommendation
HC Wainwright & Co. has reiterated a Buy rating for Alector (ALEC) and set a price target of $17.00. This analyst action reflects continued confidence in the biotechnology company. Additional details regarding the basis for the rating and target would be provided in the full report.
Alector Inc. (ALEC) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Alector Inc. (ALEC) stock, showing its current price as $2.02, up 1.00%. It also includes sections for analyst ratings, noting zero ratings in the last three months, and states that earnings information is not currently available. The page heavily promotes signing up for free trade alerts and other trading resources.
Vanguard disaggregates holdings; reports 0% in Alector (ALEC)
Vanguard has filed an amended Schedule 13G/A, reporting 0% beneficial ownership in Alector (ALEC) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, which led to certain Vanguard subsidiaries reporting their holdings separately. The filing clarifies that Vanguard no longer beneficially owns securities held by these disaggregated entities, indicating an administrative ownership clarification rather than a market transaction.
ALECTOR PB Ratio: 7.61 — 102% Above Median
Alector Inc (ALEC) currently has a Price-to-Book (PB) Ratio of 7.25 as of March 27, 2026, which is 92% above its 10-year median of 3.77. GuruFocus has rated ALEC with a GF Score™ of 37/100 and a GF Value™ of $0.85, indicating it is significantly overvalued at its current share price of $2.02. Alector's PB Ratio ranks worse than 79.68% of 1,240 Biotechnology companies, and it comes with 7 warning signs for investors.
If You Invested $1,000 in Alector (ALEC)
This article details the historical performance of investing $1,000 in Alector (ALEC) over various timeframes, showing significant losses over 5 and 10 years, despite a recent gain in the last year. It also provides an in-depth company profile of Alector, highlighting its focus on neurodegenerative diseases, its Alector Brain Carrier (ABC) platform, key clinical programs, and corporate developments including workforce reductions. The article includes frequently asked questions about the company's operations, clinical trials, and financial reporting.
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) reported a narrower-than-expected loss in Q2, while its revenues surpassed estimates. The company's net loss decreased from the prior-year quarter, and revenues also saw a significant increase. Management reiterated their financial guidance for the full year.
ALEC SEC Filings - Alector 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Alector's (ALEC) SEC filings, including 10-K, 10-Q, and 8-K reports, offering detailed insights into the biotechnology company's clinical progress, financial performance, and corporate activities. It highlights the use of AI-powered summaries to quickly extract key information from these documents and facilitates tracking of insider transactions via Form 4 filings. Recent Form 4 and Form 144 filings show sales of ALEC shares by directors and officers to cover tax obligations from RSU vesting.
